{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:52:55Z","timestamp":1794243175058,"version":"4.9.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ygyno.2019.05.004","type":"journal-article","created":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T01:29:18Z","timestamp":1558142958000},"page":"144-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Brain metastasis in epithelial ovarian cancer by BRCA1\/2 mutation status"],"prefix":"10.1016","volume":"154","author":[{"given":"Marina","family":"Stasenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Cybulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Feit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Konner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaled M.","family":"Alektiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara C.","family":"Long Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Mario M.","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Cadoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Tew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.05.004_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7150\/jca.7810","article-title":"Current approaches and challenges in managing and monitoring treatment response in ovarian cancer","volume":"5","author":"Marcus","year":"2014","journal-title":"J. Cancer"},{"key":"10.1016\/j.ygyno.2019.05.004_bb0015","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/IGC.0000000000000007","article-title":"Ovarian cancer: sites of recurrence","volume":"23","author":"Amate","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.05.004_bb0020","first-page":"2793","article-title":"Brain metastases from epithelial ovarian cancer: overview and optimal management","volume":"29","author":"Pietzner","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/B:NEON.0000014516.04943.38","article-title":"Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome","volume":"66","author":"Cohen","year":"2004","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1748-717X-8-36","article-title":"Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival","volume":"8","author":"Teckie","year":"2013","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0035","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2016.09.025","article-title":"Brain metastases in patients with EOC: clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19)","volume":"143","author":"Marchetti","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/gyno.2002.6792","article-title":"Craniotomy for central nervous system metastases in epithelial ovarian carcinoma","volume":"87","author":"Pothuri","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0045","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0050","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2009.25.1082","article-title":"Increased incidence of visceral metastases in scottish patients with BRCA1\/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype","volume":"28","author":"Gourley","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 8","key":"10.1016\/j.ygyno.2019.05.004_bb0055","first-page":"viii332","article-title":"Brain metastases in primary ovarian cancer: real-world data","volume":"29","author":"Ratner","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0060","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/IGC.0000000000000489","article-title":"Epithelial ovarian cancer metastatic to the central nervous system and a family history concerning for hereditary breast and ovarian cancer\u2014a potential relationship","volume":"25","author":"Jernigan","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.05.004_bb0065","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0070","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.05.004_bb0075","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0080","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0085","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0095","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0100","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.drudis.2015.08.005","article-title":"Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials","volume":"20","author":"Hyman","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ygyno.2019.05.004_bb0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/gim.2016.190","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics","volume":"19","author":"Kalia","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.09.011","article-title":"Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer","volume":"124","author":"Tanner","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0115","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10549-017-4206-8","article-title":"Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice","volume":"163","author":"Lim","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0120","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0125","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/bjc.2014.91","article-title":"Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules","volume":"110","author":"Murray","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.05.004_bb0130","series-title":"Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5\u20139","article-title":"The PARP inhibitor, niraparib, crosses the blood brain barrier in rodents and is efficacious in a BRCA2-mutant intracranial tumor model [abstract]","volume":"vol. 14 (12 Suppl 2)","author":"Mikule","year":"2015"},{"key":"10.1016\/j.ygyno.2019.05.004_bb0135","unstructured":"ZEJULA\u00ae (niraparib) [package insert]. Waltham, MA: Tesaro, Inc. 2017."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-015-1733-1","article-title":"Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study","volume":"122","author":"Mehta","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0145","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG oncology\/gynecologic oncology group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.05.004_bb0150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819312296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819312296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:47:11Z","timestamp":1758772031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819312296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0090825819312296"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain metastasis in epithelial ovarian cancer by BRCA1\/2 mutation status","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}